This TSX Pot Stock Could Skyrocket If It Debuts on the NYSE

A meteoric climb of Charlotte’s Web Holdings Inc. (TSX:CWEB) looms when this pot stock, a leading producer and distributor of hemp-derived CBD products, finally decide to list on the NYSE.

| More on:
Modern buildings in business district

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Is the TSX pot stock that’s a known proponent of medical marijuana NYSE-bound? While there’s no word yet, it’s fair to assume that Charlotte’s Web (TSX:CWEB) will eventually list on a major U.S. exchange. Should that happen, the pot stock could skyrocket.

The shares of the Colorado-based cannabidiol company debuted on the Canadian Securities Exchange (CSE) on August 30, 2018. On May 31, 2019, CWEB was trading on the TSX. The company’s Wall Street debut could take no longer than nine months from today.

Eye of the needle

In the U.S., Charlotte’s Web is trading over-the-counter (OTC). But it could attract institutional investors by up-listing from the OTC exchange to the main stage.

Several cannabis companies want to list on the NYSE or NASDAQ. However, it’s like passing through the proverbial eye of the needle. Applicants need to fulfill a long list of criteria. But unlike most that are uncertain of meeting the rigid requirements, Charlotte’s Web is a shoo-in when it comes to gaining acceptance.

Ripe for the spotlight

Charlotte’s Web is already the market leader in the production and distribution of innovative hemp-derived cannabidiol (CBD) wellness products. The company became popular after its CBD-containing oil was able to reduce the severe epileptic seizures of a little girl named Charlotte Figi some years back.

The report proves that Charlotte’s Web oil can improve the quality of life of children suffering from illness. Besides, there are no more roadblocks to up-listing. The industrial production of hemp and hemp-derived derivatives is perfectly legal in the U.S. after the Farm Bill became law last December.

Projected revenue growth

The market cap of Charlotte’s Web currently stands at $1.01 billion, and the shares are trading at $21.37. The company’s 2018 full-year sales grew to $69.5 million, which represents a 74% organic revenue growth. Charlotte’s Web was able to produce a record 306,818 kilograms of hemp.

This year, the company estimates sales to grow by 119% to $152 million and another 106% come 2020, which would bring total sales to $313.3 million. With over 8,000 retail locations in the U.S. and high-margin business model, you can expect CWEB to post operating profits in the coming years.

Matchless retail distribution footprint

Charlotte’s Web has the head start in a market projected to be worth US$24 billion by 2023 in America alone. The company’s partnerships with five mass retailers and other specialty retailers give it an unbeatable retail distribution footprint. Kroger, the iconic U.S. retailer, is one of CWEB’s partners.

The deal with the American retailer with a market-leading network of grocery stores is Charlotte’s Web largest distribution agreement through one retailer. Last July 30, 2019, 1,350 Kroger stores began selling Charlotte’s Web CBD products.

Whether or not the company delays its NYSE debut, growth would still accelerate. According to company CEO Deanie Elsner, there’s more to come after the successful transition to a publicly listed company and gaining market leadership in hemp CBD products.

You might consider taking a position on CWEB today before it evolves into a global consumer packaged goods (CPG) brand. The pot stock would be selling at a premium by then.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of Charlotte's Web Holdings.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »